Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194995 | 1.00 | CYP19A1 (0.70) | CYP19A1 | |
| Ethylene SCHEMBL28038914 | 0.98 | CYP19A1 (0.67) | CYP19A1 | |
| SCHEMBL28278507 | 0.90 | CYP19A1 (0.67) | CYP19A1 | |
| SCHEMBL9782731 | 0.89 | CYP19A1 (0.72) | CYP19A1 | |
| SCHEMBL9782727 | 0.89 | CYP19A1 (0.72) | CYP19A1 | |
| SCHEMBL4298015 | 0.87 | CYP19A1 (0.69) | CYP19A1 | |
| SCHEMBL7611386 | 0.87 | CYP19A1 (0.69) | CYP19A1 | |
| SCHEMBL29688557 | 0.86 | CYP19A1 (0.67) | CYP19A1 | |
| SCHEMBL28433832 | 0.86 | CYP19A1 (0.67) | CYP19A1 | |
| SCHEMBL5171014 | 0.86 | CYP19A1 (0.64) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20120028910-A1 | STORAGE-STABLE AQUEOUS OPHTHALMIC FORMULATIONS | FOVEA PHARMACEUTICALS (FR) | 2012-02-02 | — | — | US | claimed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | claimed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| WO-2024148315-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20230330084-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230174939-A1 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | STELLULAR BIO, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-11648245-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4149497-A1 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | Platelet Biogenesis, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-11576907-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-4119561-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2023-01-18 | — | — | EP | disclosed |
| WO-2002012536-A1 | MODIFIED YEASTS AND USES THEREOF, IN PARTICULAR FOR PRODUCING STEROID DERIVATIVES | AVENTIS PHARMA SA (FR) | 2002-02-14 | — | — | WO | disclosed |
| EP-0944644-A2 | PROCESSES FOR PREPARATION OF 9,11-EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN | G.D. Searle & Co. (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025948-A9 | PROCESSES FOR PREPARATION OF 9,11-EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN | — | 1998-11-19 | — | — | WO | disclosed |
| WO-1998025948-A2 | PROCESSES FOR PREPARATION OF 9,11-EPOXY STEROIDS AND INTERMEDIATES USEFUL THEREIN | G.D. SEARLE & CO. (US) | 1998-06-18 | — | — | WO | disclosed |
| WO-1991001991-A1 | NEW TOPICALLY ACTIVE STEROIDAL ANTI-INFLAMMATORY AGENTS | SRI INTERNATIONAL (US) | 1991-02-21 | — | — | WO | disclosed |
| US-4910192-A | A 12-beta substituted glucocorticoid | SRI INTERNATIONAL (US) | 1990-03-20 | — | — | US | disclosed |
| EP-0136586-A2 | Novel corticoid derivatives and process for production thereof | MITSUBISHI KASEI CORPORATION (JP) | 1985-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648245-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, GRIN3A, NR3C2 | CYP19A1 1354/4885 |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | CYP19A1 1910/4885 |
| US-11576907-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, NR3C2, NR5A1 | CYP19A1 134/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | CYP19A1 1910/4885 |
| US-20230330084-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, GRIN3A, NR3C2 | CYP19A1 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.